How to check a compound's clinical trial status yourself

ClinicalTrials.gov is public, free, and the fastest way to separate a compound with real human data behind it from one riding on preclinical hype. Here's how to read a record.

When someone claims a peptide is “in trials,” you can check. ClinicalTrials.gov is a public registry maintained by the U.S. National Library of Medicine, and a few minutes with a compound’s record will tell you far more than any marketing page. Here is what to look at.

Search by the compound, then read the record

Search the compound’s name or synonym. Each result carries an NCT identifier — an eight-digit registry number prefixed with “NCT” — that uniquely names the study. Note it; it is the citation you will use to point anyone else to the same record.

Phase tells you how far along it is

A trial’s phase describes what question it is asking:

Phase 1 studies test safety and dosing in a small group, often for the first time in humans. Phase 2 studies begin to test whether the compound does anything, in a larger group. Phase 3 studies test efficacy and monitor side effects in still larger populations, and are typically what a regulator weighs for approval. A compound in Phase 1 has cleared a very different bar than one in Phase 3 — and “in trials” flattens that distinction, which is exactly why the phrase is used.

Status tells you whether it’s active

The record’s recruitment status — recruiting, active, completed, terminated, withdrawn — tells you whether the study is live. A terminated or withdrawn trial is itself information: studies end early for reasons that range from funding to futility to safety, and the record often says which.

Results, when they exist

For completed trials, check whether results have been posted, and read the outcome measures the study pre-specified rather than any summary of them. Pre-specified endpoints are the ones that count; effects discovered after the fact carry far less weight.

What the registry cannot tell you

A registered trial is not an endorsement, and registration is not approval. A compound can have an active Phase 3 program and still be years from — or never reach — a market. The registry tells you what is being studied and how far along it is. It does not tell you the answer before the study has found one. But it does let you replace a vague claim with a verifiable status in about the time it takes to read this sentence.